Form 4: Larimar Therapeutics CEO Boosts Equity Holdings

Larimar Therapeutics' President and CEO, Carole Ben-Maimon, reported the acquisition of 100,100 restricted stock units and 600,600 stock options.

Summary

• Carole Ben-Maimon, President and CEO of Larimar Therapeutics, Inc. (LRMR), acquired 100,100 shares of Common Stock in the form of Restricted Stock Units (RSUs) on January 26, 2026, at a price of $0.00 per share.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
• Additionally, Ben-Maimon acquired 600,600 stock options on January 26, 2026, with an exercise price of $3.60 per share and a transaction price of $0.00.
• The stock options vest 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the subsequent 36 calendar months, contingent on continued service.
• Following these transactions, Ben-Maimon directly beneficially owns 368,276 shares of Common Stock.
• Indirect beneficial ownership includes 31,155 shares held by the Meadow Trust, 31,155 shares by the Olivia Trust, 31,156 shares by the Ella Trust, 31,156 shares by the Romi Trust, and 31,156 shares by the Matzi Trust, for which Ben-Maimon serves as trustee and disclaims Section 16 beneficial ownership except for pecuniary interest.
• Ben-Maimon also beneficially owns 600,600 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports a routine compensation event where the CEO receives equity awards. This is generally neutral but can be seen as slightly positive due to increased insider alignment with shareholder interests.

Positives

• The acquisition of a significant number of restricted stock units and stock options by the President and CEO aligns management's interests with those of shareholders.
• Equity-based compensation incentivizes long-term performance and commitment from key executives.

Risks

• The reporting person disclaims Section 16 beneficial ownership of shares held by various trusts (Meadow, Olivia, Ella, Romi, Matzi Trusts) except to the extent of her pecuniary interest, if any, which could introduce complexity in assessing full beneficial ownership.

Future Outlook

The vesting schedule for the acquired stock options, extending over 36 months post-January 2027, indicates an expectation of continued service from the President and CEO, aligning her incentives with the company's long-term performance.

Industry Context

The granting of restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to attract, retain, and motivate key leadership by linking their financial success to the company's stock performance.

Comparison to Industry Standards

• Equity-based compensation, including RSUs and stock options, is a prevalent component of executive remuneration packages across the biotechnology sector, similar to practices observed at comparable companies like BioNTech or Moderna, which frequently use such awards to incentivize innovation and long-term value creation.
• The vesting schedule, with an initial 25% cliff and subsequent monthly vesting, is a common structure designed to ensure executive retention and sustained commitment over several years, mirroring typical industry benchmarks for executive equity grants.

Related Party Transactions

• Shares are held by several irrevocable trusts (Meadow, Olivia, Ella, Romi, Matzi Trusts) for which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of her pecuniary interest therein.

Stakeholder Impact

• Shareholders: The equity awards align the CEO's financial interests with the company's stock performance, potentially motivating decisions that enhance shareholder value.
• Employees: The CEO's continued commitment, as implied by the vesting schedule, can foster stability and confidence within the organization.

Next Steps

• The acquired stock options will begin vesting on January 26, 2027, with subsequent monthly vesting installments over 36 months.

Key Dates

Keywords

Larimar Therapeutics, LRMR, Carole Ben-Maimon, Insider Trading, Form 4, Restricted Stock Units, Stock Options, Equity Compensation, CEO Compensation, Beneficial Ownership